Anne L. Angiolillo

Hematology | Oncology
111 Michigan Ave NW
Washington, DC 20010

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications

Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group.

Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group.

Journal: Blood advances
Published: January 26, 2026

Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.

Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.

Journal: Blood advances
Published: January 26, 2026

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

Journal: Blood advances
Published: January 08, 2026

Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

Journal: Blood advances
Published: January 07, 2026

Diminished Quality of Life Despite Reduced Treatment in Children With B-Lymphoblastic Leukemia: Children's Oncology Group AALL0932.

Diminished Quality of Life Despite Reduced Treatment in Children With B-Lymphoblastic Leukemia: Children's Oncology Group AALL0932.

Journal: Pediatric blood & cancer
Published: July 24, 2025

Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology Group.

Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology Group.

Journal: Pediatric blood & cancer
Published: May 27, 2025

Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial.

Time to recovery from neutropenia in patients with newly diagnosed IDH-1 mutated acute myeloid leukemia receiving azacitidine and ivosidenib in the AGILE clinical trial.

Journal: Leukemia research
Published: February 27, 2025

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world study.

Ivosidenib or venetoclax combined with hypomethylating agents in IDH1-mutated acute myeloid leukemia: a real-world study.

Journal: Blood neoplasia
Published: February 24, 2025

Reply to: Accurate Determinants of Outcome in ALL.

Reply to: Accurate Determinants of Outcome in ALL.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 23, 2024

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.

Journal: The New England journal of medicine
Published: December 09, 2024

Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Journal: Research square
Published: November 28, 2024

Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Journal: Leukemia
Published: October 18, 2024
Showing 1-12 of 44

Last Updated: 09/26/2026